Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19
Jorge Monserrat,
Angel Asunsolo,
Ana Gómez-Lahoz,
Miguel A. Ortega,
Jose Maria Gasalla,
Óscar Gasulla,
Jordi Fortuny-Profitós,
Ferran A. Mazaira-Font,
Miguel Teixidó Román,
Alberto Arranz,
José Sanz,
Benjamin Muñoz,
Juan Arévalo-Serrano,
José Miguel Rodríguez,
Carlos Martínez-A,
Dimitri Balomenos,
Melchor Álvarez-Mon
Affiliations
Jorge Monserrat
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain
Angel Asunsolo
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain
Ana Gómez-Lahoz
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain
Miguel A. Ortega
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain
Jose Maria Gasalla
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain
Óscar Gasulla
Hospital Universitari de Bellvitge—Universitat de Barcelona, 08907 L’Hospitalet de Llobregat, Spain
Jordi Fortuny-Profitós
Campus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain
Ferran A. Mazaira-Font
Departament d’Econometria, Estadística I Economia Aplicada—Universitat de Barcelona, 08007 Barcelona, Spain
Miguel Teixidó Román
Campus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain
Alberto Arranz
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain
José Sanz
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain
Benjamin Muñoz
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain
Juan Arévalo-Serrano
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain
José Miguel Rodríguez
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain
Carlos Martínez-A
Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, 28006 Madrid, Spain
Dimitri Balomenos
Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, 28006 Madrid, Spain
Melchor Álvarez-Mon
Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain
Objective: To describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19. Design: An observational, analytical, retrospective cohort study with longitudinal follow-up. Setting: Hospital Universitario Príncipe de Asturias (HUPA). Participants: 287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020. Main outcome measures: Profiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (n = 19), innate inflammatory IR-related cytokines (n = 27), and growth factors (n = 16). Results: A statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF. Conclusions: When severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient’s inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.